Mucormycosis in the COVID Era-HOW CYBERSIGHT CONNECTED EXPERTS IN INDIA AND WORLDWIDE

The emergence of mucormycosis as an epidemic in several parts of India made it necessary to understand the unique roles of doctors from varied specialties, among whom, an ophthalmologist's role too is to be discerned. To address this need for a common platform to discuss addressing a common challenge, Orbis leveraged its Cybersight platform.

About the Mucormycosis Webinar

Rhino-orbital-cerebral mucormycosis has emerged as an epidemic within the COVID-19 pandemic. Its treatment requires a multi-disciplinary approach and, therefore, there is a need for consensus among clinicians for a common management protocol. Orbis along with Dr Shroff’s Charity Eye Hospital, New Delhi, brought forth a special lecture which included experts from both the Orbis partner hospital and a renowned Indian multispecialty healthcare facility, Sir Ganga Ram Hospital.

Designed to provide a common platform for doctors from varied disciplines grappling with the commonly known 'black fungus', the lecture enabled experts from India to share their knowledge in the management of the condition and deliberate on a common treatment protocol.

Dr Rishi Raj Borah, Country Director observed the rare occurrence that mucormycosis must be managed by not one but several specialists of whom an ophthalmologist plays a key role. The need came into light when Orbis’s partners in India also found impact of the emerging epidemic.

The webinar brought together an ophthalmologist, radiologist, otolaryngologist, an intensivist, and a microbiologist from India battling with the common challenge. It was clear- mucormycosis needed a multi-disciplinary approach. Each of the experts described the need and perspective of their specialties to bring positive patient outcome to light.

Topics covered

412 participants from 82 countries

With multiple threats to lives through COVID second wave in India and state level lockdowns across the country, healthcare experts receive a ready platform, like Cybersight, to come together. India’s current battle helps the case of several other countries having patients with mucormycosis.

Making such a resource available for both Indian healthcare providers and global healthcare providers makes it an extremely crucial global platform during such trying times.

It is no surprise to see 412 participants join from 82 countries with over 100 participants from India.

412 participants from 82 countries

Professionals across the globe in attendance

103

participants from India

309

participants from 81 other countries

What some of the attending participants had to say

Todo (sobre el webinar) está excelente [Everything (about the webinar) is excellent]

Webinar Participant

Everything is perfect for me

Webinar Participant

It (The webinar) was good and knowledgeable

Webinar Participant

Join Cybersight today

register now for free